Q1 EPS Estimates for Henry Schein Cut by Leerink Partnrs

Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Leerink Partnrs dropped their Q1 2025 earnings estimates for shares of Henry Schein in a research report issued on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $1.12 per share for the quarter, down from their previous estimate of $1.14. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Leerink Partnrs also issued estimates for Henry Schein’s Q2 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.16 EPS, FY2025 earnings at $4.61 EPS and FY2028 earnings at $6.00 EPS.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the prior year, the business posted $0.66 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year.

A number of other research analysts also recently weighed in on HSIC. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and increased their target price for the company from $69.00 to $84.00 in a report on Monday, January 6th. StockNews.com upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Wednesday. Barrington Research restated an “outperform” rating and set a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. Wells Fargo & Company initiated coverage on shares of Henry Schein in a research report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. Finally, UBS Group cut their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday, February 26th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Henry Schein currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.10.

Henry Schein Stock Performance

HSIC stock opened at $64.46 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49. The company has a market cap of $8.00 billion, a P/E ratio of 26.53, a price-to-earnings-growth ratio of 2.13 and a beta of 0.84. The stock’s fifty day moving average price is $71.90 and its 200-day moving average price is $72.23.

Insider Transactions at Henry Schein

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. This represents a 9.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares in the company, valued at $4,460,251.20. This trade represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

Several institutional investors have recently added to or reduced their stakes in HSIC. Versant Capital Management Inc raised its stake in Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $32,000 after purchasing an additional 335 shares in the last quarter. Investment Management Corp VA ADV purchased a new position in shares of Henry Schein in the 4th quarter worth $32,000. Venturi Wealth Management LLC increased its holdings in shares of Henry Schein by 3,347.1% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock worth $41,000 after buying an additional 569 shares during the last quarter. Quent Capital LLC raised its position in shares of Henry Schein by 91.2% during the 4th quarter. Quent Capital LLC now owns 677 shares of the company’s stock valued at $47,000 after buying an additional 323 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after acquiring an additional 143 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.